Self-Administered Gaming and Exercise at Home (SAGEH)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorJohns Hopkins University

About this trial

This study aims at comparing manual function outcomes between the standard of care and additional self-administered hand therapy after stroke. Strokes are common neurological injuries, and although rates of survival have increased in recent decades, survivors often continue to experience deficiencies in hand dexterity and bimanual function. Most motor recovery takes place within the first 3 months after a stroke. This initial period is necessary for stabilizing the patient but also provides different opportunities to foster motor recovery. Functional gains, including instances after the post-acute period, have been observed after regular and frequent (high dosage) therapy, suggesting that recovery is likely influenced by practice-driven sensorimotor learning. These findings motivate the implementation of daily therapeutic regimes beyond post-stroke hospitalization and basic motor function, aiming instead at addressing overlooked deficiencies in manipulation and bimanual coordination. While some hand therapy is often provided during outpatient therapy visits (the standard of care), self-administered sessions play a large role in implementing additional daily therapy. As a result, the investigators are interested in both the implementation of self-administered regimes and measuring clinical outcomes with and without self-administered therapy.

Eligibility criteria

Qualifiers

Age 21 years and over

Stroke confirmed by CT or MRI within the previous 6 weeks.

Arm and/or hand impairment induced by the stroke.

Meet JSTTEP criteria and are enrolled in JSTTEP.

Disqualifiers

Arm impairment that is too severe (FM-UE < 40) on day of baseline testing prior to beginning of the study.

Recent Botox injection to upper limb (since stroke onset).

History of physical or neurological condition that interferes with study procedures or assessment of motor function (e.g. severe arthritis, severe neuropathy, Parkinson's disease).

Terminal illness with life expectancy < 6 months.

Trial design

Treatments tested in this trial

  • NoNo
  • occupational therapy - self directed

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Johns Hopkins University

Lead sponsor

Sheikh Khalifa Stroke Institute

Collaborator